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ABSTRACT
Background: Existence of bacterial host-cell DNA contamination in biopharmaceutical products is a potential risk 
factor for patients receiving these drugs. Hence, the quantity of contamination must be controlled under the 
regulatory standards. Although different methods such as hybridization assays have been employed to determine 
DNA impurities, these methods are labor intensive and rather expensive. In this study, a rapid real-time PCR test 
was served as a method of choice to quantify the E. coli host-cell DNA contamination in widely used recombinant 
streptokinase (rSK), and alpha interferon (IFN-α) preparations. Methods: A specific primer pair was designed to 
amplify a sequence inside the E. coli 16S rRNA gene. Serial dilutions of DNA extracted from E. coli host cells, along 
with DNA extracted from Active Pharmaceutical Ingredients of rSK, and IFN-α samples were subjected to an 
optimized real-time PCR assay based on SYBR Green chemistry. Results: The test enabled us to detect a small 
quantity of genomic DNA contamination as low as 0.0002 pg in recombinant protein-based drugs. For the first 
time, this study showed that DNA contamination in rSK and IFN-α preparation manufactured in Pasteur Institute 
of Iran is much lower than the safety limit suggested by the US FDA. Conclusion: Real-time PCR is a reliable test 
for rapid detection of host-cell DNA contamination, which is a major impurity of therapeutic recombinant proteins
to keep manufacturers’ minds on refining drugs, and provides consumers with safer biopharmaceuticals.
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INTRODUCTION
herapeutic recombinant products are extensively
used for human medical purposes. Recombinant 
proteins can be expressed in various types of 
living organisms[1,2]. Escherichia coli is one of the 
most commonly used host cells for the manufacture of 
biopharmaceuticals due to its well-characterized 
genetic map[3-5]. Although using E. coli for the 
production of therapeutics has many advantages, 
contamination of biopharmaceuticals with bacterial 
DNA has become a major concern for manufacturers. 
Genomic DNA contamination in biopharmaceuticals 
has been considered as a possible risk factor[6]. It has 
been supposed that DNA contaminants may be 
integrated into the genome of patient’s recipient cells 
and express a new foreign gene or alter the level of 
gene expression[7]. 
It is, therefore, crucial for biopharmaceutical 
industries to monitor DNA contamination[8] and keep 
the quantity of impurities in bioproducts as low as a 
safety limit suggested by the regulatory authorities 
such as FDA, which must be lower than 100 pg of 
DNA per milligram of protein[9]. Generally, the 
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hybridization assay and total DNA threshold assay 
have been used for the quantitative detection of host 
cell DNA in pharmaceuticals; however, these methods 
are time-consuming and expensive[10].
In recent years, great interests have been focused on 
real-time PCR assay as a new method for simultaneous 
detection and quantification of PCR products[11]. Real-
time PCR has been employed for detection of bacterial, 
and viral loads in therapeutic proteins[12-16]. In this 
study, we established a novel sensitive real-time PCR 
test based on SYBR Green chemistry to detect a small 
quantity of E. coli host-cell DNA contamination in rSK 
and IFN-α samples produced at Pasteur Institute of 
Iran. Streptokinase and interferon are protein-based 
drugs produced in E. coli host cells[17,18]. Streptokinase 
is used as an intravenous thrombolytic agent for 
treatment of acute myocardial infarction[19]. Interferon 
acts as an integral part of the innate immune response
and targets specific cell-surface receptors[20], which are
conducive to the interferon-mediated antiviral 
response[21].
MATERIALS AND METHODS
Cell culture
E. coli W3110 strain was provided from Pasteur 
Institute of Iran. As the first step of normalization, a
single colony of the cells was used to inoculate into 5
ml of Luria-Bertani broth. The colony was incubated at 
37ºC overnight with shaking at 250 rpm until the 
optical density at 600 nm reached 3.0, which was 
approximately equivalent to 2.4×109 cells/ml (Perkin-
Elmer Lambda UV/visible Spectrophotometer, Applied 
Biosystems, UK).
Preparation of E. coli genomic DNA
Cells were precipitated by centrifugation at 17226 ×g
for 2 min. Genomic DNA was isolated using DNeasy 
Blood and Tissue Kit (Qiagen, Germany) according to 
the manufacturer’s protocol. At the second step of 
normalization, Optical density (260/280 nm and 
260/230 nm) and concentration were measured using a 
NanoPhotometer 2000c (Thermo Science, USA).
Primer design and PCR test
In this study, four sets of forward and reverse 
primers were designed for the conserved region of the 
eubacteria 16S rRNA gene using Primer Express
software (Foster City, USA). The sequence 
information is found in the NCBI GenBank database 
(Accession Number: J01859). The specific 
oligonucleotide primers were designed for the 
conserved region of 16S rRNA gene (Table 1), and 
primer pairs were synthesized by Bioneer Corporation
(Korea). All primer pairs were used in different PCR 
runs from the viewpoint of primer dimmer formation.
Among the designed primers, the primer pair 16S2
displayed higher specificity and efficiency with 
minimal primer pair formation.
PCR reaction was carried out in a Mastercycler 
Personal (Eppendorf, Germany). The cycle parameters 
were as follows: initial heat denaturation at 94ºC for 1
min, followed by 35 cycles of denaturation at 94ºC for
20 s, annealing at 60ºC for 30 s, and extension at 72ºC 
for 30 s. To ensure the complete extension, reaction 
mixture was incubated at 72ºC for 5 min. Genomic 
DNA (10 ng) was amplified in a total volume of 20 µl
mixture containing 10 pM each of forward and reverse 
primer (0.5 µl), 10 µl Ex Taq Master Mix 2× (Takara, 
Japan, and 8 µl nuclease free water. PCR products 
were analyzed by electrophoresis on 1.5% agarose gel 
(Sigma, USA).
Optimization of real-time PCR
In order to normalize and calculate primer efficiency, 
different concentrations of primer pairs were assessed.
In this assay, SYBR Green I was used as a fluorescent 
dye. Real-time PCR reactions were carried out via an 
ABI 7300 real-time PCR instrument (Applied 
Biosystems, USA).
Amplification efficiency was validated using five-
fold serial dilutions of DNA template as 2000, 400, 80, 
16, 3.2, 0.64, 0.128, 0.025, 0.005, 0.001, and 0.0002
pg. Standard curve was drawn by plotting the 
logarithmic input DNA concentration versus mean 
cycle of threshold (mCt). Subsequently, the slope of 
standard curve was determined and PCR efficiency
was calculated using the formula; E = (10[-1/slope]-1)× 
100.
Optimum reaction condition in a total volume of 20
µl was obtained with 10 pM each forward and reverse 
primer (0.5 µl), 10 µl SYBR Green PCR Master Mix 
2× (Takara, Japan) containing Taq DNA polymerase, 
SYBR Green I, Tris-HCl, MgCl2, KCl, and 
deoxynucleotide triphosphate, 0.4 µl ROX dye (6-
Carboxy-x-rhodamine), 7.6 µl nuclease-free water, and 
1 µl template genomic DNA. Thermal cycling program
was performed with an initial heat denaturation at 95˚C 
for 1 min, followed by 40 cycles of denaturation at 
95˚C for 20 s, and combined annealing/extension at 
60˚C for 35 s and 95ºC for 15 s, 60ºC for 1 min and 
95ºC for 15 s. In the melting stage, temperatures were
raised 0.5ºC for each step. Dissociation stage was 
performed after the amplification stage to verify the 
specificity of the PCR products. Each amplicon was 
identified by its specific melting curve Tm. A reaction
including PCR Master Mix and nuclease-free water
was used as non-template control in each experiment.
All reactions were run in duplicate.
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  Table 1. Sequences of oligonucleotide primer pairs
Forward primer Reverse primer
Nucleotide 
position
product 
size (bp)
16S-F1 AGAAGCTTGCTCTTTGCTGA 16S-R1 CTTTGGTCTTGCGACGTTAT 78-197 120
16S-F2 AAAGGAGACTGCCAGTGATA 16S-R2 AGGTCGCTTCTCTTTGTATG 1149-1263 115
16S-F3 CATTGACGTTACCCGCAGAA 16S-R3 CGCTTTACGCCCAGTAATTCC 476-576 101
16S-F4 CCATGAAGTCGGAATCGCTAG 16S-R4 ACTCCCATGGTGTGACGG 1326-1419 94
DNA extraction from therapeutic proteins
Due to the presence of inhibitory agents in final 
products, DNA was extracted from Active 
Pharmaceutical Ingredients of rSK and IFN-α samples. 
To achieve this purpose, five batches of each drug, 
which were produced for five successive weeks, were 
selected for DNA purification. After phenol/
chloroform extraction, the supernatant was transferred 
into a microcentrifuge tube. Then, DNA was 
precipitated using 400 µl isopropanol. After washing 
twice with 700 µl ethanol, DNA pellets were 
suspended in nuclease-free water.
Detection of DNA contamination
DNA templates, including 1 µl each serially diluted 
E. coli genomic DNA, 1 µl DNA extracted from rSK, 
and 1 µl DNA extracted from IFN-α were subjected to 
real-time PCR test. The total volume of each reaction 
mixture was 20 µl containing 10 pM each forward and 
reverse primer (0.5 µl), SYBR Green PCR Master Mix 
2 × (10 µl), ROX dye (0.4 µl), nuclease-free water (7.6
µl), and 1 µl DNA template. All reactions were run in 
duplicate, and non-template controls were added to the 
experiment. Cycling conditions were hold at 95ºC for 1
min, followed by 40 cycles at 95ºC for 20 s, and 60ºC 
for 35s. PCR products were visualized on 1.5%
agarose gel.
Validation of real-time PCR
According to the FDA guidelines for industry, 
namely bioanalytical method, validation, the 
reproducibility, precision, linearity, and detection limit 
of the real-time PCR assay were validated. E. coli 
genomic DNA (100 µg) was fragmented using HindIII 
and EcoRI enzymes, and fragmented DNA was used as 
the standard DNA. The reproducibility and precision 
were measured using 50 and 100 pg of E. coli genomic 
DNA (gDNA), and the concentration of samples were 
measured three times on different days. The mCt
values, and average of standard deviations (SD) were 
also calculated.
For detection of linearity, standard samples 
containing 2000, 400, 80, 16, 3.2, 0.64, 0.128, 0.025, 
0.005, 0.001, and 0.0002 pg of E. coli gDNA, along 
with negative samples, were prepared. The 
concentrations of samples were obtained three times on 
different days. Standard curves were plotted for each 
experiment, and the correlation coefficient was 
calculated using least square method.
The detection limit was evaluated using minimum 
level of concentration at which the samples can be 
detected. Standard samples containing 2000 to 0.0002
pg of genomic DNA, along with negative solutions, 
were used for the validation of real-time PCR assay.
RESULTS
Amplification of DNA extracted from rSK and 
IFN-α
Serially five-fold dilution of E. coli genomic DNA 
from 2000 to 0.0002 pg, one pair of negative controls, 
and DNA extracted from rSK and IFN-α preparations 
were run in duplicate (Fig. 1A). Melting curve analysis 
of PCR products did not show any primer-dimer 
formation (Fig. 1B). Moreover, this graph 
demonstrated melting of amplification fragment at 
83.9ºC. The post-PCR analysis confirmed and showed 
the target fragment (115 bp) without non-specific 
products (Fig. 2).
The slope of standard curve, y-intercept, 
determination of coefficient (R2), and PCR efficiency
were obtained as -2.63, 25.64, 0.99, and 100%, 
respectively. Standard curve presented Ct values (mean 
± SD) between 15.58 ± 0.163 and 34.03 ± 0.037 (Fig. 
1C).
Quantitative detection of DNA contamination
The mean of two Ct values (mCt) obtained from 
duplicate amplification of DNA extracted from each 
rSK and IFN-α was calculated separately. The mCt 
values (32.89 and 33.28 for rSK and IFN-α,
respectively) were put instead of “Y” values in the 
standard curve equation (Y = -2.63X + 24.72) to 
calculate “X” values. After getting the common 
logarithm of “X” values, the estimated amounts of E.
coli host-cell DNA contamination in rSK and IFN-α 
preparation were 0.0012 and 0.0017 pg per mg of 
products, respectively (Table 2). The values calculated 
from the experiments were much lower than the limit 
permitted by the FDA[9].
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Fig. 1. Specificity of real-time PCR test for the quantity of DNA contamination in biopharmaceuticals; (A) Amplification plot of 5-
fold serial diluted E. coli genomic DNA concentrations along with the amplification plot of DNA extracted from therapeutic proteins; 
1, 2000 pg; 2, 400 pg; 3, 80 pg; 4, 16 pg; 5, 3.2 pg; 6, 0.64 pg; 0.0128 pg; 8, 0.025 pg; 9, 0.005 pg; 10. 0.001 pg; 11. 0.0002 pg; A, 
Alpha interferon; B, Streptokinase; (B) Melting curve analysis of PCR products; (C) Standard curve.
Validation of real-time PCR
In the present study, some quality control 
procedures, including the reproducibility, precision, 
detection limit, and linearity of real-time PCR method
were performed. The reproducibility was determined 
by calculating the mCt values as 19.17, 19.64, and 
18.88 for 50 pg of standard DNA, and 20.33, 20.44, 
and 20.12 for 100 pg of standard DNA on different 
days (Table 3). The precision was evaluated as 50.67
±1.28 and 101.12 ± 1.44 for 50 and 100 pg of standard 
DNA, respectively (Table 4). The linearity was 
calculated by a standard curve using the least square 
method. The mean value of the correlation coefficient 
obtained   from three experiments was 0.99.
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Fig. 2. Gel electrophoresis of PCR products. Lane 1, 2000 pg; Lane 2, 400 pg; Lane 3, 80 pg; Lane 4, 16 pg; Lane 5, 3.2 pg; Lane 6, 
0.64 pg; Lane 7, 0.128 pg; Lane 8, 0.025 pg; Lane 9; 0.005 pg, Lane 10; 0.001 pg, Lane 11; 0.0002 pg, NC; negative control, M; 
marker.
Table 2. DNA content of recombinant protein-based drugs
Recombinant 
protein
Drug concentration
(mg/ml)
DNA content
(pg/mg of product)
rSK 1.2 0.0012
IFN-α 1.1 0.0017
The detection limit of the assay was 0.0002 pg of 
DNA. The range of the standard curve was from 
0.0002 to 2000 pg of DNA.
DISCUSSION
Therapeutic recombinant proteins are widely used 
for human therapies. Host-cell genomic DNA 
contamination in biopharmaceuticals is a potential risk 
factor for consumers. Therefore, FDA and other 
regulatory agencies have defined specific quality 
control and safety criteria, which manufacturers are 
required to quantify DNA impurities in recombinant 
therapeutics at different stages of production[22,23]. To 
detect the minimum amount of impurities, the
method involved in the quantitative detection of DNA
contamination must be accurate and sensitive enough.
For a few years, radioactive-based expensive 
methods, including the species-specific DNA 
hybridization assay, have been used to quantify 
bacterial host-cell DNA contamination in biopharma-
ceuticals [10]. Ji et al.[24], reported a safe non-
radioactive slot-blot hybridization assay to quantify E.
coli DNA contamination levels in purified protein-
based drugs with a sensitivity to detect 2.5pg E.coli
DNA. Afterwards, Gregory et al.[25] described a safer 
and less-expensive alternative method, i.e. PCR 
amplification and dioxygenin labeling of the genes 
encoding 5S rRNA followed by an affinity-based
collection, for detection of 1 pg/mL of the extracted 
E.coli genomic DNA[25]. Although the Gregory's 
method seemed sensitive, it was capital-intensive to be 
applied routinely in the biopharmaceutical industries. 
This made researchers to search for even more 
inexpensive assays that might be applied readily by 
manufacturers. Real-time PCR has recently been 
reported as an alternative method for simultaneous 
detection and quantification of DNA sequence in 
manufactured products.In this study, a novel real-time 
PCR test, based on SYBR Green chemistry, was 
established for the precise measurement of E. coli host-
cell DNA contamination in two widely used
recombinant protein-based drugs, i.e. rSK and 
IFN-α. Despite the fact that real-time PCR has many
                                  Table 3. The reproducibility of assay
Concentration of standard
DNA (pg)
mCt
Day 1 Day 2 Day 3
50 19.17 19.64 18.88
100 20.33 20.44 20.12
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Table 4. The precision of assay
Concentration of 
standard DNA (pg)
Concentration of calculated 
DNA (mean ± SD)
50   50.67 ± 1.28
100 101.12 ± 1.44
privileges, it has not been employed routinely in the 
pharmaceutical industries, mainly because real-time 
PCR reactions may be inhibited by various agents that 
are present in biopharmaceuticals[26]. In this 
experiment, to eliminate the inhibitory effect of the 
agents, E. coli genomic DNA was first extracted from 
the Active Pharmaceutical Ingredients of 
biopharmaceuticals and then was subjected to real-time 
PCR test. Using this method, we are able to detect 
reliably a very small amount of bacterial genomic 
DNA. The gene copy number was calculated according 
to the molecular mass of the E. coli genome, namely 
2.86×109 Da or 4.7491×10-3 pg. There are seven 
genomic copies of the 16S rRNA gene in each 
bacterium[27], and the molecular mass of each copy is 
6.79×10-4 pg. Thus, the sensitivity of our assay was 
0.0002 pg equivalent to 1 copy of the 16S rRNA gene 
(equivalent to one E. coli bacterium). Although some 
kinds of probes, including those labeled with 
fluorescent dyes, can significantly enhance the 
specificity of real-time PCR[28,29], we exploited SYBR 
Green chemistry to establish an inexpensive detection 
assay. It is known that primer-dimer formation is one 
of the major problems using SYBR Green dye. To 
avoid this problem, we optimized the real-time PCR 
reaction condition by designing accurate primers as 
well as by finding the most effective salt concentration
(4 mM), primer concentration (10 pM), optimal 
annealing temperature and time (60ºC for 35 s).
In conclusion, we have succeeded to establish a new 
real-time PCR approach based on SYBR Green 
chemistry for measurement of E. coli genomic DNA
impurities in biopharmaceuticals, with a detection limit 
of 0.0002 pg DNA per mg of therapeutic recombinant 
proteins. The present study show that E. coli host-cell 
DNA contamination in rSK and IFN-α manufactured at
Pasteur Institute of Iran is much lower than the safety 
limit suggested by FDA.
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